Analysis of renal impairment in MM-003, a phase III study of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in refractory or relapsed and refractory multiple myeloma by Weisel, Katja C et al.
872 haematologica | 2016; 101(7)
Received: December 15, 2015. 
Accepted: April 12, 2016.
Pre-published: April 14, 2016.
©2016 Ferrata Storti Foundation
Check the online version for the most updated
information on this article, online supplements,
and information on authorship & disclosures:
www.haematologica.org/content/101/7/872
Material published in Haematologica is cov-
ered by copyright. All rights are reserved to the
Ferrata Storti Foundation. Copies of articles
are allowed for personal or internal use.
Permission in writing from the publisher is










ARTICLE Plasma Cell Disorders
doi:10.3324/haematol.2015.137083
Pomalidomide + low-dose dexamethasone is effective and well toler-ated for refractory or relapsed and refractory multiple myeloma afterbortezomib and lenalidomide failure. The phase III trial MM-003
compared pomalidomide + low-dose dexamethasone with high-dose
dexamethasone. This subanalysis grouped patients by baseline creatinine
clearance ≥ 30 - < 60 mL/min (n=93, pomalidomide + low-dose dexam-
ethasone; n=56, high-dose dexamethasone) or ≥ 60 mL/min (n=205,
pomalidomide + low-dose dexamethasone; n=93, high-dose dexametha-
sone). Median progression-free survival was similar for both subgroups
and favored pomalidomide + low-dose dexamethasone 
versus high-dose dexamethasone: 4.0 versus 1.9 months in the group with
baseline creatinine clearance ≥ 30 - < 60 mL/min (P<0.001) and 4.0 versus
2.0 months in the group with baseline creatinine clearance ≥ 60 mL/min
(P<0.001). Median overall survival for pomalidomide + low-dose dexam-
ethasone versus high-dose dexamethasone was 10.4 versus 4.9 months
(P=0.030) and 15.5 versus 9.2 months (P=0.133), respectively. Improved
renal function, defined as an increase in creatinine clearance from < 60 to
≥ 60 mL/min, was similar in pomalidomide + low-dose dexamethasone
and high-dose dexamethasone patients (42% and 47%, respectively).
Improvement in progression-free and overall survival in these patients
was comparable with that in patients without renal impairment. There
was no increase in discontinuations of therapy, dose modifications, and
adverse events in patients with moderate renal impairment.
Pomalidomide at a starting dose of 4 mg + low-dose dexamethasone is
well tolerated in patients with refractory or relapsed and refractory multi-
ple myeloma, and of comparable efficacy if moderate renal impairment is
present. This trial was registered with clinicaltrials.gov identifier 01311687
and EudraCT identifier 2010-019820-30.
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ABSTRACT
Introduction
Renal impairment is a common presenting feature for
patients with multiple myeloma (MM). Approximately
20% to 40% of patients with newly diagnosed MM, who
are primarily aged over 65 years, have renal impairment at
diagnosis, and this rate increases during the course of dis-
ease.1-4 Renal impairment as a complication of MM often
leads to cast nephropathy, potentially resulting in renal
tube atrophy and tubulointerstitial fibrosis.5,6 In addition,
impaired renal function may be a result of aging and can
also be caused by comorbidities unrelated to MM, such as
diabetes, hypertension, vascular disease, or prior non-
myeloma therapies.3 Renal impairment in patients with
MM is associated with shortened survival, but recovery of
renal function during treatment may improve survival in
these patients and even achieve similar outcomes in
patients with a history of normal renal function.3,4,7 
The past several decades have seen advances in the treat-
ment of MM, and outcomes have improved for patients
with varying degrees of renal impairment;3,8 despite this,
most patients will ultimately relapse.9,10 Control of MM via
effective therapy has been shown to improve renal function
in a large proportion of patients.11,12 However, patients who
are refractory to bortezomib and have relapsed following
treatment with an immunomodulatory agent, or patients
who are refractory to or ineligible to receive an
immunomodulatory agent, have a poor prognosis (median
survival 9 months).13 Physicians may perceive that treat-
ment options in these patients may be further limited by
the presence of renal impairment, as some novel agents rely
on metabolism/excretion by the kidneys.7
Pomalidomide (POM) acts via direct antimyeloma, stro-
mal-support inhibitory, and immunomodulatory
effects.14,15 POM in combination with low-dose dexam-
ethasone (LoDEX) was evaluated for the treatment of
relapsed and refractory MM in patients after lenalidomide
and bortezomib failure in the MM-002 and MM-003 stud-
ies. The phase I component of MM-002 established the
maximum tolerated dose for POM at 4 mg daily with or
without LoDEX (40 mg weekly).16 This dose was moved
forward into an open-label, randomized, phase II compo-
nent, which found POM + LoDEX to be more efficacious
than POM alone [overall response rate (ORR) 33% vs.
18%; median progression-free survival (PFS) 4.2 vs. 2.7
months; median overall survival (OS) 16.5 vs. 13.6
months]. The pivotal, multicenter, open-label, random-
ized, phase III study MM-003 verified the safety and effi-
cacy of POM + LoDEX (n=302) compared with high-dose
dexamethasone (HiDEX; n=153) in patients with refracto-
ry or relapsed and refractory MM previously treated with
(and 74% refractory to) lenalidomide and bortezomib.17
Overall trial results included significant improvements in
ORR (31% vs. 10%; P<0.0001), PFS (4.0 vs. 1.9 months;
P<0.0001), and OS (12.7 vs. 8.1 months; P=0.0285).17
Preliminary pharmacokinetic data suggest that renal
impairment probably does not impact on POM exposure.18
The aim of the current analysis was to examine efficacy
and safety of POM + LoDEX versus that of HiDEX in
patient subgroups enrolled in MM-003 by renal function at
baseline [creatinine clearance (CrCl) ≥ 30 - < 60 mL/min vs.
≥ 60 mL/min]. In addition, we examined median PFS and
OS in patients who had improvement of renal function
from CrCl ≥ 30 - < 60 mL/min at baseline to ≥ 60 mL/min
at any point during study treatment.
Methods
MM-003 was an open-label, randomized, phase III trial con-
ducted in 93 centers in Europe, Russia, Australia, Canada, and the
United States (clinicaltrials.gov identifier: 01311687; EudraCT 2010-
019820-30). Full details have been described previously.17 All
authors and the study sponsor were involved in data collection
and  analysis, review and interpretation of results, and the writing
of the report.
Patients
Eligible patients were aged 18 years or over with refractory or
relapsed and refractory MM, had measurable serum or urine M
protein, and were refractory to their last prior treatment [docu-
mented progressive disease (PD) during or within 60 days of last
therapy]. Prior bortezomib and lenalidomide treatment (≥ 2 con-
secutive cycles, alone or in combination) must have failed [i.e.
refractory (never experienced a response), PD within six months
after at least a  partial response (PR), or intolerant (to bortezomib
only)]. Adequate prior alkylator therapy was required.
Exclusion criteria included: absolute neutrophil count < 1x109/L;
platelets < 75x109/L (< 30x109/L if ≥ 50% of bone marrow nuclea-
ted cells were plasma cells); CrCl < 45 mL/min; peripheral neu-
ropathy grade ≥ 2; prior exposure to POM; hypersensitivity to
thalidomide, lenalidomide, or DEX; or resistance to DEX.
Study design and treatment
Patients were randomized 2:1 to POM + LoDEX (28-day cycles;
oral POM: 4 mg/day, days 1-21; LoDEX: 40 mg/day, days 1, 8, 15,
and 22) or HiDEX (40 mg/day, days 1-4, 9-12, and 17-20). For
patients aged over 75 years, DEX dose was reduced to 20 mg/day
in both treatment arms. Patients continued treatment until PD or
unacceptable toxicity. Thromboprophylaxis was required for all
patients receiving POM and any patient at high risk of developing
thrombosis. 
Patients provided written informed consent. The study received
institutional review board or independent ethics committee
approval at all participating centers according to the Declaration of
Helsinki and the International Conference on Harmonisation
Guidelines on Good Clinical Practice.
Subgroup analyses
In this retrospective analysis, renal impairment cohorts included
patients with moderate renal impairment (baseline CrCl ≥ 30 - <
60 mL/min) or without renal impairment (baseline CrCl ≥ 60
mL/min), based on the Cockroft-Gault formula.19,20 CrCl data
were collected prospectively and were estimated at the start of
each treatment cycle and upon discontinuation.
Assessments
The primary end point was investigator-assessed PFS. Survival
distribution functions for each treatment group were estimated
with the Kaplan-Meier product-limit method and compared with
the log-rank test. Key secondary end points included OS, ORR [≥
PR by International Myeloma Working Group (IMWG) criteria],
safety [adverse events (AEs) graded according to National Cancer
Institute Common Terminology Criteria for Adverse Events v.4.0],
and improvement of renal function from CrCl ≥ 30 - < 60 mL/min
at baseline to ≥ 60 mL/min at any point during study treatment
(only assessed in patients with baseline and post-baseline CrCl
data). As an additional retrospective analysis, renal response was
assessed according to IMWG criteria.5 Efficacy was assessed in the
intent-to-treat population (all patients randomized to treatment)
using IMWG criteria, and tolerability was assessed in the safety
population (all patients who received ≥ 1 dose of study drug). PFS
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and OS for patients with renal improvement were calculated
according to European Medicines Evaluation Agency criteria.
Statistical analyses were performed using SAS software v.9.2.
Results
Patients' characteristics
This analysis was performed using a data cut off of
September 1st, 2013, corresponding to a median follow up
of 15.4 months. A total of 302 patients received POM +
LoDEX, and 153 patients received HiDEX (Online
Supplementary Figure S1). Patients were heavily pre-treated,
with a median of 5 prior lines of treatment in all groups.
For patients with baseline CrCl ≥ 30 - < 60 mL/min, data
were available for 93 POM + LoDEX and 56 HiDEX
patients. For those with baseline CrCl ≥ 60 mL/min, data
were available for 205 POM + LoDEX and 93 HiDEX
patients. Eight patients were not included in the analysis:
3 patients had missing baseline CrCl values (2 in the POM-
LoDEX arm and 1 in the HiDEX arm), and 5 patients had
baseline CrCl levels below 30 mL/min (2 in the POM-
LoDEX arm and 3 in the HiDEX arm) (Online
Supplementary Figure S1). Patients with baseline CrCl ≥ 30
- < 60 mL/min were more likely to be older and less likely
to have undergone prior SCT compared with patients
with baseline CrCl ≥ 60 mL/min (Table 1). The moderate
renal impairment cohort also exhibited higher rates of
International Staging System stage II-III disease, Eastern
Cooperative Oncology Group status of 3, and high-risk
cytogenetics.
Efficacy
Median PFS with POM + LoDEX versus HiDEX was con-
sistent in patients with baseline CrCl ≥ 30 - < 60 mL/min
(4.0 vs. 1.9 months; P<0.001) (Figure 1A) and ≥ 60 mL/min
(4.0 vs. 2.0 months; P<0.001) (Figure 1B). POM + LoDEX
also improved median OS compared with HiDEX in
patients with baseline CrCl ≥ 30 - < 60 mL/min (10.4 vs. 4.9
months; P=0.030) (Figure 2A) and ≥ 60 mL/min (15.5 vs. 9.2
months; P=0.133) (Figure 2B). The OS advantage of POM +
LoDEX over HiDEX was achieved despite a substantial pro-
portion of HiDEX patients receiving subsequent POM
(50% of HiDEX patients with baseline 
CrCl ≥ 30 - < 60 mL/min and 60% of HiDEX patients with
baseline CrCl ≥ 60 mL/min crossed over to POM + LoDEX).
POM + LoDEX significantly improved ORR versus HiDEX
regardless of baseline renal function (Table 2). Duration of
response (for patients achieving ≥ PR) was consistently
longer for POM + LoDEX versus HiDEX in both groups.
Improvement in renal function
A total of 273 patients in the POM + LoDEX arm and
128 patients in the HiDEX arm had CrCl data for baseline
and ≥ 1 post-baseline assessment and were thus evaluable
for change in renal function (for patients with > 1 post-
baseline assessment, the best value during the first 6 cycles
was used). Renal improvement to CrCl ≥ 60 mL/min was
noted in 42% of patients (33 of 79) treated with POM +
LoDEX who had renal impairment (CrCl < 60 mL/min) at
baseline (Table 3). Renal improvement was seen in 47%
(20 of 43) of HiDEX-treated patients. The median time to
improvement was similar for each treatment arm (POM +
LoDEX: 1.0 month; HiDEX: 0.9 months). In these POM +
LoDEX and HiDEX-treated patients with renal improve-
ment, median PFS was 6.5 (95%CI: 4.6, 8.4) and 3.2
(95%CI: 2.1, 5.5) months, respectively; median OS was
12.6 (95%CI: 7.6, 25.7) and 10.1 (95%CI: 5.7, 17.7)
months, respectively.
According to IMWG criteria for renal response,5 32%
(14 of 44) of POM + LoDEX-treated patients with estimat-
ed glomerular filtration rate (eGFR) < 50 mL/min/1.73 m2
achieved complete response of CrCl ≥ 60 mL/min (Table
3). In a similar analysis of the HiDEX-treated patients,
43% (9 of 21) achieved a complete response. Few or no
patients in either treatment arm were eligible for partial or
minimal response by having baseline eGFR < 30
mL/min/1.73 m2.
Safety
The AE profiles for POM + LoDEX and HiDEX were
similar across both renal function subgroups (Table 4). The
most common grade 3/4 AEs for the POM + LoDEX treat-
ment arm were neutropenia (48% for baseline CrCl ≥ 30 -
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Table 1. Baseline patients’ characteristics and prior therapies.
Patients’ characteristics Baseline CrCl Baseline CrCl
≥ 30 - < 60 mL/min ≥ 60 mL/min
POM + LoDEX HiDEX POM + LoDEX HiDEX
(n=93) (n=56) (n=205) (n=93)
Median age (range), years 69 (41-84) 69 (36-87) 61 (35-80) 61 (35-80)
Male sex, % 46 45 67 65
Median time from initial diagnosis, years 5.5 5.8 5.3 6.2
ECOG status 0/1/2/3, %a 39/38/23/0 16/59/21/4 36/50/14/0 30/56/13/1
ISS stage at study entry I/II/III, %a 11/38/51 11/28/61 36/42/22 33/45/22
Median prior treatments (range), n 5 (2-12) 5 (2-17) 5 (2-14) 5 (2-16)
Prior LEN/BORT/DEX, % 100/100/99 100/100/100 100/100/97 100/100/99
Prior SCT, % 60 57 76 79
LEN refractory, % 99 89 93 94
BORT refractory, % 77 84 80 76
LEN and BORT refractory, % 76 79 74 71
Presence of del(17p)/t(4;14), % 30 34 23 17
BORT: bortezomib; CrCl: creatinine clearance; DEX: dexamethasone; ECOG: Eastern Cooperative Oncology Group; HiDEX: high-dose dexamethasone; ISS: International Staging
System; LEN: lenalidomide; LoDEX: low-dose dexamethasone; POM: pomalidomide; SCT: stem cell transplant. aPercentages based on number of patients with data available. 
< 60 mL/min and 49% for baseline CrCl ≥ 60 mL/min),
anemia (40% and 30%, respectively), and infections (31%
and 34%, respectively). With mandatory thromboprophy-
laxis, incidence of grade 3/4 deep vein thrombosis/pul-
monary embolism was low (≤ 2% in both groups). 
POM discontinuations and dose modifications due to
AEs were similar regardless of moderate renal impairment
(Table 5). Median duration of POM treatment was similar
in patients with baseline CrCl ≥ 30 - < 60 mL/min (3.7
months) and ≥ 60 mL/min (4.6 months). Renal function
did not affect frequency of dose reductions and interrup-
tions. Median relative dose intensity was consistent at
90% for both renal function subgroups.
Discussion
POM + LoDEX was efficacious and well tolerated in
patients with refractory or relapsed and refractory MM
and moderate renal impairment. POM + LoDEX signifi-
cantly extended PFS versus HiDEX for all patients regard-
less of renal impairment (baseline CrCl ≥ 30 - < 60
mL/min, 4.0 vs. 1.9 months; baseline CrCl > 60 mL/min,
4.0 vs. 2.0 months; P<0.001 for both groups), similar to the
benefits observed in the general study population (4.0 vs.
1.9 months; P<0.001).17 OS results showed a similar 5- to
6-month benefit for POM + LoDEX in both renal function
subgroups (baseline CrCl ≥ 30 - < 60 mL/min, 10.4 vs. 4.9
Renal impairment in the phase III MM-003 study
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Table 2. Response to treatment (IMWG criteria).
Variable Baseline CrCl Baseline CrCl
≥ 30 - < 60 mL/min ≥ 60 mL/min
POM + LoDEX HiDEX POM + LoDEX HiDEX
(n=93) (n=56) (n=205) (n=93)
ORR (≥ PR), % 28 11 34 12
sCR 0 0 1 0
CR 0 0 2 0  
VGPR 7 0 5 1
PR 22 11 26 11
SD, % 52 48 50 50
Median DOR, monthsa 6.6 4.4 7.5 5.1
CR: complete response; CrCl: creatinine clearance; DOR: duration of response; HiDEX: high-dose dexamethasone; IMWG: International Myeloma Working Group; LoDEX: low-dose
dexamethasone; ORR: overall response rate; POM: pomalidomide; PR: partial response; sCR: stringent complete response; SD: stable disease; VGPR: very good partial response. aFor
patients with ≥ PR.
Figure 1. Progression-free survival for patients
with baseline creatinine clearance ≥ 30 - < 60

























months; baseline CrCl > 60 mL/min, 15.5 vs. 9.2 months)
compared with those of the overall patient population
(13.1 vs. 8.2 months),17 although these results were only
statistically significant for patients with reduced renal
function (baseline CrCl ≥ 30 - < 60 mL/min, P=0.030; base-
line CrCl > 60 mL/min, P=0.133). This finding is likely to
be confounded by the high number (56% overall) of
HiDEX patients crossing over to receive POM after pro-
gression, as per protocol.
A substantial number of renally impaired patients treat-
ed with POM + LoDEX had improved renal function (42%
per protocol criteria and 32% per IMWG criteria), which
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Figure 2. Overall survival for patients with baseline creatinine clearance ≥ 30 - < 60 mL/min (A) or ≥ 60 mL/min (B). 
A
B
Table 3. Improvement in renal function.
Category Baseline Best POM + LoDEX, HiDEX, 
renal function renal function n/N (%)a n/N (%)a
Per-protocol improvement CrCl < 60 mL/min CrCl ≥ 60 mL/min 33/79 (42) 20/43 (47)
IMWG CRrenal eGFR < 50 mL/min/1.73 m2 CrCl ≥ 60 mL/min 14/44 (32) 9/21 (43)
IMWG PRrenal eGFR < 15 mL/min/1.73 m2 CrCl 30-59 mL/min 0/3 0/1
IMWG MRrenal eGFR < 15 mL/min/1.73 m2 CrCl 15-29 mL/min 0/0 0/0
eGFR 15-29 mL/min/1.73 m2 CrCl 30-59 mL/min
CrCl: creatinine clearance; CRrenal: complete renal response; eGFR: estimated glomerular filtration rate; HiDEX: high-dose dexamethasone; IMWG: International Myeloma Working
Group; LoDEX: low-dose dexamethasone; MRrenal: minimal renal response; POM: pomalidomide; PRrenal: partial renal response. aPercentages represent patients who improved from
baseline to most extreme post-baseline value, divided by the total number of patients with evaluable baseline and post-baseline data. 
was similar to the improvement rate noted in the HiDEX
arm. HiDEX treatment can rapidly suppress M-protein
and light-chain excretion leading to recovery of renal func-
tion and can be used for acute myeloma treatment.12,21,22 In
the present study, however, response rates in renally
impaired patients greatly favored the POM+LoDEX arm
compared with the HiDEX arm: 28% versus 11%, respec-
tively. In patients treated with POM + LoDEX whose kid-
ney function improved from moderate impairment to nor-
mal, PFS reached 6.5 months, which exceeded the results
of patients with normal baseline kidney function (4.0
months). Despite a similar proportion of patients with
renal improvement noted in the HiDEX arm, their PFS was
only 3.2 months. The OS improvement observed in these
patients was in the same range as that in patients with
normal renal function.  
Tolerability profiles were consistent regardless of base-
line renal function. Rates of discontinuation due to AEs
were similar in both subgroups, indicating that patients
with moderate renal impairment did not experience
increased toxicity. Slightly increased incidences of pneu-
monia were observed in patients with baseline CrCl ≥ 30
- < 60 mL/min. Duration of treatment and dose intensity
were not affected by baseline renal function. These find-
ings demonstrate that up-front dose modification is not
required in patients with moderate renal impairment, and
that 4 mg is a safe and appropriate starting dose of POM
in combination with LoDEX for these patients.
The efficacy results of POM + LoDEX in renal function
subgroups of MM-003 confirm those found previously. In
the phase II component of MM-002, patients without
renal impairment (baseline CrCl > 60 mL/min) had an
ORR of 34%, median PFS of 5.4 months, and median OS
of 16.9 months, and patients with moderate renal impair-
ment (baseline CrCl ≥ 45 to ≤ 60 mL/min) had an ORR of
43%, median PFS of 4.7 months, and median OS of 19.5
months. It should be noted, however, that there were only
14 patients in this subgroup in that study.23 Safety profiles
and relative dose intensities for these subgroups were con-
sistent between the phase II study and the one presented
here.23 This cumulative body of evidence regarding POM
+ LoDEX further supports use of a 4-mg starting dose for
patients with mild or moderate renal impairment without
up-front dose reduction. 
The finding that POM does not require dose adjustment
in patients with moderate renal impairment versus patients
with normal renal function is related to its metabolism and
excretion. In contrast to lenalidomide, which is excreted
primarily via the kidneys,24 POM is extensively metabo-
lized (with only 2.2% excreted as the parent drug in urine)
and, therefore, does not require dose reductions in
patients with impaired renal function;18,25 the same obser-
Renal impairment in the phase III MM-003 study
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Table 4. Safety profile.
Event Baseline CrCl Baseline CrCl
≥ 30 - < 60 mL/min ≥ 60 mL/min
POM + LoDEX HiDEXa POM + LoDEX HiDEXa
(n=93) (n=56) (n=203) (n=90)
Grade 3/4 hematologic AEs in ≥ 10% of pts, %
Neutropenia 48 21 49 16
Anemia 40 46 30 34
Thrombocytopenia 22 38 23 20
Febrile neutropenia 5 0 11 0
Grade 3/4 non-hematologic AEs in ≥ 10% of pts, %
Infections 31 27 34 24
Pneumonia 19 9 11 8
Grade 3/4 AEs of interest, %
DVT/PE 1 0 2 0
Peripheral neuropathyb 1 2 2 1
Discontinuation due to AEs, % 13 11 8 10
AE: adverse event; CrCl: creatinine clearance; DVT: deep vein thrombosis; HiDEX: high-dose dexamethasone; LoDEX: low-dose dexamethasone; PE: pulmonary embolism; POM:
pomalidomide; pt: patient. aPatients may have received POM + LoDEX after crossover. bPeripheral neuropathy includes the preferred terms “hyperesthesia,” “neuropathy peripheral,”
“peripheral sensory neuropathy,” “paresthesia,” “hypoesthesia,” and “polyneuropathy.” 
Table 5. Pomalidomide dose modification due to adverse events and dose intensity.
Variable Baseline CrCl Baseline CrCl
≥ 30 - < 60 mL/min ≥ 60 mL/min
(n=93) (n=203)





Planned POM dose/day, mg 4 4
Median relative dose intensity (range)a 0.9 (0.4-1.3) 0.9 (0.3-1.2)
Median duration of treatment (range), months 3.7 (0.1-21.4) 4.6 (0.1-25.6)
AEs: adverse event; CrCl: creatinine clearance; POM: pomalidomide. aRelative dose intensity = dose intensity/planned dose intensity. May be more than 1 due to patient discontinu-
ation prior to end of 28-day cycle. 
vation applies to thalidomide.26,27 The safety profile of
POM + LoDEX as assessed in the study presented here
demonstrated no difference in frequency of dose reduc-
tions in patients with moderate renal impairment and only
slightly higher rates of anemia and pneumonia. 
However, this analysis was limited by the fact that it
concerns only patients with normal or moderately
impaired renal function, as the study excluded patients
with CrCl < 45 mL/min at the time of screening [although
28 (9%) POM + LoDEX and 15 (10%) HiDEX patients had
baseline CrCl below this cut off due to the time that had
elapsed between screening and the first treatment cycle].
To address this, 2 trials are in progress to assess the use of
POM + LoDEX in patients with severe renal impairment,
including those requiring dialysis: MM-008  in the United
States (clinicaltrials.gov identifier 01575925) and MM-013  in
the European Union (clinicaltrials.gov identifier 02045017). 
Newer treatment options, including lenalidomide,
thalidomide, and bortezomib, have improved outcomes
and survival for many patients with MM in recent
years.28,29 In addition, although newer agents can improve
outcomes, including renal function, for many patients
with MM with renal impairment,5,7 it remains a significant
risk factor for early death in MM.3,30 Thus, the efficacy of
POM + LoDEX in renally impaired relapsed/refractory
MM populations is of particular importance. This analysis
has demonstrated that a starting dose of POM 4 mg may
be used safely regardless of moderate renal impairment,
with no unexpected toxicities observed and no additional
dose modifications or discontinuations required when
compared with the overall trial population. PFS and OS
benefits achieved by patients with moderate renal impair-
ment were also consistent with the overall MM-003 trial
population.
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